Clinical Trial Detail

NCT ID NCT03693170
Title encorAfenib, biNimetinib and Cetuximab in Subjects witH previOusly Untreated BRAF-mutant ColoRectal Cancer (ANCHOR-CRC)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Pierre Fabre Medicament
Indications

colorectal cancer

Therapies

Binimetinib + Cetuximab + Encorafenib

Age Groups: adult senior

Additional content available in CKB BOOST